Effects of trazodone on viability in healthy and malignant ovarian cells


Çobankaya H.

Aegean Journal of Medical Sciences, cilt.6, sa.3, ss.68-72, 2023 (ESCI)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 6 Sayı: 3
  • Basım Tarihi: 2023
  • Doi Numarası: 10.33713/egetbd.1332111
  • Dergi Adı: Aegean Journal of Medical Sciences
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI)
  • Sayfa Sayıları: ss.68-72
  • Hacettepe Üniversitesi Adresli: Evet

Özet

OBJECTIVE: Trazodone is a triazole pyridine derivative antidepressant, the design of which dates back to the 1980s. It is mainly
used in the treatment of major depression, as well as in psychological disorders such as anxiety, insomnia, and schizophrenia.
Considering how widespread the use of antidepressants is, it sensible to evaluate the effects of this group of drugs in different
pathologies other than the disease group they target. C ancer is the most common cause of death in the world after cardiovascular
diseases. The use of trazodone in cancer patients and the relationship between the use of trazodone and the development of
cancer have been reported in various studies. However, these studies are mostly observational and population-based and the
molecular effects of trazodone in the cancer model are not clearly known.
MATERIALS AND METHODS: Trazodone was applied to healthy ovarian cells and OVCAR-3 and A2780 ovarian cancer cell lines at
a certain dose range (0.1-20 μM). Viability in cells treated and untreated with trazodone was analyzed by MTT assay.
RESULTS: The results revealed that trazodone treatment (0.1-20 μ M) d id n ot h ave a significant e ffect o n h ealthy and cancerous
ovarian cell viability.
CONCLUSION: Trazadone (0.1-20 μM) does not significantly affect the viability of both healthy and cancer cells.
Keywords: trazodone, OVCAR-3, A2780, ovarian, cancer, viability